Lay Summary: Not much is known about NK1 T lymphomas. This post briefly describes what is known.
This kind of lymphoma tend to be indolent but not all that much is known about hatural history of these neoplasms and some patients do poorly. Patients with natural killer T (NK/T) -cell lymphomas have poor survival outcome, and for this condition there is no optimal therapy. A recent review found that following treatments tend to be used: Patients received one of the following initial treatment modalities: (1) an anthracycline-containing chemotherapeutic regimen followed by radiotherapy (RT); (2) a non–anthracycline-containing chemotherapeutic regimen followed by RT; (3) anthracycline-based chemotherapy; (4) non–anthracycline-based chemotherapy; (5) involved-field RT as the primary treatment; (6) surgery alone; and (7) supportive care only. The anthracycline-based regimens used were as following: cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP); dose-escalated CHOP (deCHOP); cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin, procarbazine (COPBLAM); and (etoposide, doxorubicin, vincristine, cyclophosphamide, prednisolone (EPOCH). The non–anthracycline-containing regimens used were ifosfamide, methotrexate, etoposide (IMEP); dexamethasone, ifosfamide, cisplatin, etoposide (DICE); etoposide, methylprednisolone, cisplatin, cytarabine (ESHAP); dexamethasone, cytarabine, cisplatin (DHAP); etoposide, ifosfamide, cisplatin, dexamethasone (VIPD); and cyclophosphamide, vincristine, prednisone (CVP). In patients with localized disease, involved-field radiotherapy was given at the physician’s discretion following chemotherapy. The treatment response was assessed according to standard response criteria.
An ongoing study of EPOCH/CaMPATH is referenced below. The proposed study is described briefly as follows: “This study will examine the safety and effectiveness of combination therapy with the monoclonal antibody Campath-1H and continuous infusion of a chemotherapy regimen called EPOCH for treating non-Hodgkin’s T-cell and NK-cell lymphomas. In general, T-cell and NK-cell lymphomas are less responsive to standard treatments than B-cell lymphomas. EPOCH, which includes the drugs doxorubicin, etoposide, vincristine, cyclophosphamide, and prednisone, has shown a high degree of effectiveness in patients whose tumors have stopped responding to standard regimens. Campath-1H may improve the effects of chemotherapy.”
Stem Cell transplantation is in the infant stages for this disease.
Jeeyun Lee, Cheolwon Suh, Yeon Hee Park, Young H. Ko, Soo Mee Bang, Jae Hoon Lee, Dae Ho Lee, Jooryung Huh, Sung Yong Oh, Hyuk-Chan Kwon, Hyo Jin Kim, Soon Il Lee, Jung Han Kim, Jinny Park, Seok Joong Oh, Kihyun Kim, Chulwon Jung, Keunchil Park, Won Seog Kim
Extranodal Natural Killer T-Cell Lymphoma, Nasal-Type: A Prognostic Model From a Retrospective Multicenter Study Journal of Clinical Oncology, Vol 24, No 4 (February 1), 2006: pp. 612-618
Au WY, Lie AKW, Liang R, et al: Autologous stem cell transplantation for nasal NK/T-cell lymphoma: A progress report on its value. Ann Oncol 14:1673-1679, 2003
L. Pagano, A. Gallamini, G. Trape, L. Fianchi, D. Mattei, G. Todeschini, A. Spadea, S. Cinieri, E. Iannitto, M. Martelli, A. Nosari, E. D. Bona, M. E. Tosti, M. C. Petti, P. Falcucci, M. Montanaro, A. Pulsoni, L. M. Larocca, G. Leone, and For the Intergruppo Italiano Linfomi NK/T-cell lymphomas ‘nasal type’: an Italian multicentric retrospective survey Ann. Onc., May 1, 2006; 17(5): 794 – 800.